EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours ^☆

TY - JOUR

T1 - EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours ☆

AU - EANO Executive Board and ESMO Guidelines Committee

AU - Le Rhun, E.

AU - Guckenberger, M.

AU - Smits, M.

AU - Dummer, R.

AU - Bachelot, T.

AU - Sahm, F.

AU - Galldiks, N.

AU - de Azambuja, E.

AU - Berghoff, A. S.

AU - Metellus, P.

AU - Peters, S.

AU - Hong, Y. K.

AU - Winkler, F.

AU - Schadendorf, D.

AU - van den Bent, M.

AU - Seoane, J.

AU - Stahel, R.

AU - Minniti, G.

AU - Wesseling, P.

AU - Weller, M.

AU - Preusser, M.

N1 - Funding Information: ELR has received honoraria for lectures or advisory board from AbbVie, Adastra, Daiichi Sankyo, LEO Pharma, Seagen and Tocagen. MG has received honoraria for lectures or advisory board from AstraZeneca and has received research support from AstraZeneca and Varian. MS received honoraria for lectures from GE Healthcare and for trial imaging review from Parexel Ltd. RD has intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, CatalYm, Second Genome, Regeneron and Alligator. TB has received personal fees and non-financial support from Roche; grants, personal fees and non-financial support from Novartis, AstraZeneca and Pfizer; and grant and personal fees from Seattle Genetics. ASB has research support from Daiichi Sankyo and Roche and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck and Daiichi Sankyo as well as travel support from Roche, Amgen and AbbVie. EdA has received honoraria and/or advisory board from Roche/GNE, Novartis, Seattle Genetics, Zodiac, Libbs, Lilly and Pierre Fabre; travel grants from Roche/GNE and GSK/Novartis; and research grants to her institution from Roche/GNE, AstraZeneca, GSK/Novartis and Servier. SP has received education grants, provided consultation, attended advisory boards, provided lectures for and received honoraria from AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, PharmaMar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda and Vaccibody. FS has received advisory board for AbbVie, travel support from Agilent and Illumina and speaker’s bureau from Agilent and Medac. DS reported consulting or advisory role for Roche/Genentech, Novartis, Bristol-Myers Squibb, MSD, Merck Serono, Amgen, Immunocore, Incyte, InFlarX, 4SC, Pierre Fabre, Mologen, Nektar and Sanofi/Regeneron; honoraria from Roche/Genentech, Novartis, MSD, Bristol-Myers Squibb, Merck Serono, Amgen, Immunocore, Incyte, 4SC, Pierre Fabre, Array BioPharma, Pfizer, Philogen and Regeneron; travel, accommodation and expenses from Roche/Genentech, Novartis, Bristol-Myers Squibb, Merck Serono, Amgen and Merck; speakers’ bureau for Novartis, Bristol-Myers Squibb, MSD, Pierre Fabre and Roche; research funding from Novartis and Bristol-Myers Squibb; and steering committee member for Novartis, MSD and Bristol-Myers Squibb. JS is a co-founder of Mosaic Biomedicals and board member of Northern Biologics; he received grant/research support from Mosaic Biomedicals, Northern Biologics, Roche/Glycart, Isarna and Ridgeline. RS has received honoraria for lectures or advisory board from boards from MSD, Roche, Merck Serono, Celldex Therapeutics, Novartis, Mundipharma and Puma Technologies. MvdB has received honoraria for consultation from AbbVie, Agios, Carthera, Celgene, Bayer, Nerviano, Karyopharm and Boehringer. FW has received research grants from Roche, Genentech, Boehringer and Divide & Conquer Ltd. and honoraria from Divide & Conquer Ltd. MW has received research grants from AbbVie, Adastra, Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD) and Novocure and honoraria for lectures or advisory board participation or consulting from AbbVie, Basilea, Bristol Meyer Squibb (BMS), Celgene, Medac, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Roche and Tocagen. MP has received honoraria for lectures, consultation or advisory board participation from Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome and Tocagen and reported clinical trials and contracted research (paid to his institution) from Böhringer-Ingelheim, Bristol-Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GlaxoSmithKline and AbbVie. The remaining authors have declared no conflicts of interest. Funding Information: Manuscript editing support was provided by Sarah Escuin, Richard Lutz, Jennifer Lamarre and Catherine Evans (ESMO Guidelines staff). No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. ELR has received honoraria for lectures or advisory board from AbbVie, Adastra, Daiichi Sankyo, LEO Pharma, Seagen and Tocagen. MG has received honoraria for lectures or advisory board from AstraZeneca and has received research support from AstraZeneca and Varian. MS received honoraria for lectures from GE Healthcare and for trial imaging review from Parexel Ltd. RD has intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, CatalYm, Second Genome, Regeneron and Alligator. TB has received personal fees and non-financial support from Roche; grants, personal fees and non-financial support from Novartis, AstraZeneca and Pfizer; and grant and personal fees from Seattle Genetics. ASB has research support from Daiichi Sankyo and Roche and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck and Daiichi Sankyo as well as travel support from Roche, Amgen and AbbVie. EdA has received honoraria and/or advisory board from Roche/GNE, Novartis, Seattle Genetics, Zodiac, Libbs, Lilly and Pierre Fabre; travel grants from Roche/GNE and GSK/Novartis; and research grants to her institution from Roche/GNE, AstraZeneca, GSK/Novartis and Servier. SP has received education grants, provided consultation, attended advisory boards, provided lectures for and received honoraria from AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer-Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, PharmaMar, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda and Vaccibody. FS has received advisory board for AbbVie, travel support from Agilent and Illumina and speaker's bureau from Agilent and Medac. DS reported consulting or advisory role for Roche/Genentech, Novartis, Bristol-Myers Squibb, MSD, Merck Serono, Amgen, Immunocore, Incyte, InFlarX, 4SC, Pierre Fabre, Mologen, Nektar and Sanofi/Regeneron; honoraria from Roche/Genentech, Novartis, MSD, Bristol-Myers Squibb, Merck Serono, Amgen, Immunocore, Incyte, 4SC, Pierre Fabre, Array BioPharma, Pfizer, Philogen and Regeneron; travel, accommodation and expenses from Roche/Genentech, Novartis, Bristol-Myers Squibb, Merck Serono, Amgen and Merck; speakers’ bureau for Novartis, Bristol-Myers Squibb, MSD, Pierre Fabre and Roche; research funding from Novartis and Bristol-Myers Squibb; and steering committee member for Novartis, MSD and Bristol-Myers Squibb. JS is a co-founder of Mosaic Biomedicals and board member of Northern Biologics; he received grant/research support from Mosaic Biomedicals, Northern Biologics, Roche/Glycart, Isarna and Ridgeline. RS has received honoraria for lectures or advisory board from boards from MSD, Roche, Merck Serono, Celldex Therapeutics, Novartis, Mundipharma and Puma Technologies. MvdB has received honoraria for consultation from AbbVie, Agios, Carthera, Celgene, Bayer, Nerviano, Karyopharm and Boehringer. FW has received research grants from Roche, Genentech, Boehringer and Divide & Conquer Ltd. and honoraria from Divide & Conquer Ltd. MW has received research grants from AbbVie, Adastra, Dracen, Merck, Sharp & Dohme (MSD), Merck (EMD) and Novocure and honoraria for lectures or advisory board participation or consulting from AbbVie, Basilea, Bristol Meyer Squibb (BMS), Celgene, Medac, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Roche and Tocagen. MP has received honoraria for lectures, consultation or advisory board participation from Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome and Tocagen and reported clinical trials and contracted research (paid to his institution) from Böhringer-Ingelheim, Bristol-Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GlaxoSmithKline and AbbVie. The remaining authors have declared no conflicts of interest.

PY - 2021/11

Y1 - 2021/11

KW - central nervous system

KW - cerebral

KW - clinical practice

KW - guideline

KW - neurological

KW - recommendations

UR - http://www.scopus.com/inward/record.url?scp=85114662933&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.07.016

DO - 10.1016/j.annonc.2021.07.016

M3 - Article

C2 - 34364998

AN - SCOPUS:85114662933

SN - 0923-7534

VL - 32

SP - 1332

EP - 1347

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -